Galapagos N.V.
- BID
24.72
- ASK
24.9
- 163 Units163 Units
- 07/23, 21:59:46 PM
Sector and Industry
Healthcare, Biopharmaceuticals
Performance (1Y)
9.76%
Market Cap
1.66 Bil.
P/E Ratio
5.75
Dividend Yield
0.00 %
Earnings per Share
4.87 €
Peer Group
| Company Name | Market Cap | Revenue Last Reported Year | P/E Ratio | Profit Growth 1Y | Last Price | Previous Trading Day Change |
|---|---|---|---|---|---|---|
| Eli Lilly and Company | 864.54 Bil. | 57.78 Bil. | 46.82 | +86.88 % | 0.00 | - |
| Johnson & Johnson | 425.70 Bil. | 83.48 Bil. | 18.82 | +82.71 % | 0.00 | - |
| AbbVie Inc. | 343.94 Bil. | 54.21 Bil. | 96.78 | -5.29 % | 0.00 | - |
| Roche Holding AG | 286.62 Bil. | 65.80 Bil. | 20.72 | +58.45 % | 0.00 | - |
| AstraZeneca PLC | 244.91 Bil. | 52.09 Bil. | 27.55 | +39.41 % | 0.00 | - |
| NOVARTIS AG | 224.76 Bil. | 48.44 Bil. | 18.30 | +12.45 % | 0.00 | - |
| Merck & Co. Inc. | 221.79 Bil. | 57.55 Bil. | 14.46 | +2.25 % | 0.00 | - |
| Novo-Nordisk AS B | 193.52 Bil. | 41.49 Bil. | 14.11 | +1.54 % | 0.00 | - |
| Amgen Inc. | 150.16 Bil. | 32.57 Bil. | 23.01 | +80.77 % | 0.00 | - |
| Gilead Sciences Inc. | 129.70 Bil. | 26.10 Bil. | 18.10 | +1,599.93 % | 0.00 | - |
Facts & figures
Price data
| TRADE PLATFORM | Börse Stuttgart (XSTU) | |
| LAST PRICE | 24.68 G | 0 Units |
| PRICE DETERMINATION TIME | 07/23/2026 / 09:56:14 PM | |
| DAILY VOLUME (UNITS) | 0 | |
| DAILY HIGH / LOW | 25.58 | 24.66 |
| PREV. DAY'S PRICE | 25.16 | (07/22) |
| CHANGE DAY BEFORE | -0.48 | -1.91 % |
| 52 WEEK HIGH / LOW | 31.8 (10/03) | 22.62 (05/18) |
Key Figures (in EUR)
| 2023 | 2024 | 2025 | 2026e | 2027e | |
|---|---|---|---|---|---|
EARNINGS PER SHARE | 3.21 | 1.12 | 4.87 | -2.87 | -2.81 |
DIVIDENDS PER SHARE | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
DIVIDEND YIELD IN % | 0.00 % | 0.00 % | 0.00 % | - | - |
DIVIDEND GROWTH IN % | - | - | - | - | - |
PRICE - EARNINGS RATIO | 11.51 | 23.59 | 5.75 | - | - |
PRICE - BOOK RATIO | 0.87 | 0.60 | 0.57 | - | - |
PRICE - SALES RATIO | 10.17 | 6.34 | 1.66 | - | - |
PRICE - CASH FLOW RATIO | - | - | - | - | - |
Master Data
| WKN | A0EAT9 |
| ISIN | BE0003818359 |
| SYMBOL | GXE |
| EXCHANGE SEGMENT | Freiverkehr |
| TYPE OF FINANCIAL INSTRUMENT | Equity |
| DENOMINATION | Galapagos Genomics |
| INDEX MEMBERSHIP | - |
| TRADING SEGMENT | - |
| TRADING HOURS | 07:30:00 AM - 10:00:00 PM |
| TRADING CURRENCY | Euro |
| NOMINAL CURRENCY | Euro |
| SETTLEMENT CURRENCY | Euro |
| SECTOR AND INDUSTRY | Healthcare, Biopharmaceuticals |
| NUMBER OF SHARES | 65.90 Mil. |
| MARKET CAPITALISATION | 1.66 Bil. |
Performance overview
| 1W | 1M | 3M | 6M | 1Y | 3Y | 5Y | YTD | |
|---|---|---|---|---|---|---|---|---|
| PERFORMANCE | -1.72 % | 0.96 % | 1.45 % | -13.54 % | -9.76 % | -34.41 % | -50.60 % | -9.95 % |
| HIGH | 26.12 | 26.88 | 26.88 | 30.44 | 31.80 | 39.47 | 65.74 | 30.44 |
| LOW | 25.16 | 24.76 | 22.62 | 22.62 | 22.62 | 20.42 | 20.42 | 22.62 |
Dividende
pro Aktie
Galapagos Genomics does not deliver dividend information
Company profile
Lakefront Biotherapeutics is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. Its clinical pipeline includes filgotinib, GLP3667, Toledo program, and idiopathic pulmonary fibrosis. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.
Structured products for Galapagos N.V.
Analyst Rating
Ø-Target Price DistanceNot Available
Current Price
Not AvailableØ-Target Price
Not AvailableAverage ResultNot Available
Buy0
Overweight0
Hold0
Underweight 0
Sell0
Company Events
No company events available.